Long-term study of a weight-loss medication for people who completed an earlier trial
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the 72-week visit in the original MARITIME-2 study.
- You must not have stopped taking the study drug early in the previous trial.
- You must be willing to use birth control while on the drug and for 16 weeks after your last dose.
- You cannot have had surgery or a device placed for weight loss planned during this study.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study compares two versions of an investigational weight-loss injection to see if they are absorbed similarly. It is an early-stage trial for adults with a BMI of 25 or higher who want to help improve future treatments.
This study tests whether people with obesity or overweight can safely and effectively give themselves the study medicine (called maridebart cafraglutide) at home using a pre-filled autoinjector pen. It is being studied as a weight-loss treatment for adults who have struggled to lose weight with diet and exercise alone.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
This study compares two newer once-weekly injectable medicines to see which one works better for lowering blood sugar in people with type 2 diabetes. You may join if your blood sugar is not well controlled on your current diabetes pills.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.